<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163292">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972439</url>
  </required_header>
  <id_info>
    <org_study_id>HS-07-00269</org_study_id>
    <nct_id>NCT00972439</nct_id>
  </id_info>
  <brief_title>Oral Contraceptive (OC) Progestin Dose and Breast Proliferation</brief_title>
  <official_title>Evaluating the Effect of Oral Contraceptive Progestin Dose on Breast Epithelial Cell Proliferation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to gain a better understanding of the changes that may
      occur in the breast when a woman uses an oral contraceptive (birth control pill). Some
      research indicates that women who use birth control pills with lower amounts of progestin (a
      hormone in the birth control pill) may have lower breast cell growth than women who use
      birth control pills with a higher amount of progestin; this research will examine that in
      detail.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure breast cell proliferation levels between the two oral contraceptive dose groups.</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Oral Contraceptive</condition>
  <arm_group>
    <arm_group_label>Ortho-Novum® 1/35</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovcon Fe®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovcon Fe® is an oral contraceptive that contains less progestin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive: Ortho-Novum® 1/35</intervention_name>
    <arm_group_label>Ortho-Novum® 1/35</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive: Ovcon Fe®</intervention_name>
    <arm_group_label>Ovcon Fe®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-34.

          2. Premenopausal.

          3. Currently taking or want to start oral contraceptives for contraception

          4. Non-smoker.

          5. Competent to give informed consent (as judged by the investigator).

          6. Provided written informed consent.

          7. Willingness to refrain from smoking and consumption of grapefruit or grapefruit juice
             during the study (grapefruit interferes with metabolism of exogenously administered
             OCs).

        Exclusion Criteria:1.

          1. Abnormal breast examination.

          2. History or current therapeutic or prophylactic use of anticoagulants.

          3. Known bleeding disorder or history of unexplained bleeding or bruising.

          4. History of breast cancer or previous diagnostic breast biopsy.

          5. Known allergy to local anesthetic.

          6. Currently pregnant or pregnant within the previous 6 months.

          7. Having any standard contra-indication to being prescribed OCs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DeShawn Taylor, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County Hospital</name>
      <address>
        <city>Los Angelses</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <lastchanged_date>September 4, 2009</lastchanged_date>
  <firstreceived_date>September 3, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Malcolm C. Pike Ph.D., USC Professor</name_title>
    <organization>University of Southern California</organization>
  </responsible_party>
  <keyword>Oral Contraceptives</keyword>
  <keyword>Breast Tissue</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Mestranol</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
